These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 26219406)
1. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells. Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406 [TBL] [Abstract][Full Text] [Related]
2. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells. Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633 [TBL] [Abstract][Full Text] [Related]
3. Heat Shock Protein 90 Inhibitors AUY922, BIIB021 and SNX5422 Induce Bim-mediated Death of Thyroid Carcinoma Cells. Kim SH; Cho YK; Huh JH; Kang JG; Ihm SH; Choi MG; Lee SJ Anticancer Res; 2020 Nov; 40(11):6137-6150. PubMed ID: 33109551 [TBL] [Abstract][Full Text] [Related]
4. Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cells. Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ Biomed Pharmacother; 2016 Oct; 83():22-32. PubMed ID: 27470546 [TBL] [Abstract][Full Text] [Related]
5. Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells. Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ J Endocrinol Invest; 2018 Jun; 41(6):677-689. PubMed ID: 29147952 [TBL] [Abstract][Full Text] [Related]
6. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. Lin SF; Lin JD; Chou TC; Huang YY; Wong RJ PLoS One; 2013; 8(10):e77684. PubMed ID: 24155971 [TBL] [Abstract][Full Text] [Related]
7. Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells. Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Lee SJ Endocrine; 2019 Jul; 65(1):110-120. PubMed ID: 31102069 [TBL] [Abstract][Full Text] [Related]
8. The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells. Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ Endocrine; 2015 Apr; 48(3):886-93. PubMed ID: 25096912 [TBL] [Abstract][Full Text] [Related]
9. 17-Allylamino-17-demethoxygeldanamycin and Herbimycin A Induce Cell Death by Modulating β-Catenin and PI3K/AKT Signaling in FRO Anaplastic Thyroid Carcinoma Cells. Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ Anticancer Res; 2015 Oct; 35(10):5453-60. PubMed ID: 26408708 [TBL] [Abstract][Full Text] [Related]
11. Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer. Kim SM; Park KC; Jeon JY; Kim BW; Kim HK; Chang HJ; Choi SH; Park CS; Chang HS BMC Cancer; 2015 Dec; 15():1003. PubMed ID: 26698299 [TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line. Zhang QC; Jiang SJ; Zhang S; Ma XB Asian Pac J Cancer Prev; 2012; 13(7):3471-6. PubMed ID: 22994780 [TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling. Zhang P; Guo Z; Wu Y; Hu R; Du J; He X; Jiao X; Zhu X PLoS One; 2015; 10(8):e0136193. PubMed ID: 26287365 [TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539 [TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239 [TBL] [Abstract][Full Text] [Related]
17. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma. Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546 [TBL] [Abstract][Full Text] [Related]
18. Cytotoxic effect of celastrol alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells. Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ Tumour Biol; 2017 May; 39(5):1010428317698369. PubMed ID: 28459364 [TBL] [Abstract][Full Text] [Related]
19. Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells. Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ Tumour Biol; 2017 Feb; 39(2):1010428317692252. PubMed ID: 28218042 [TBL] [Abstract][Full Text] [Related]
20. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]